Balance disorder

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

Retrieved on: 
Tuesday, March 21, 2023
TENS, Prevalence, DSM-IV codes, IQR, American Academy, Falls, Patient, Balance disorder, Fibromyalgia, FDA, Memory, Conference, Fatigue, Pharmaceutical industry

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL.

Key Points: 
  • WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL.
  • In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented.
  • Quell Fibromyalgia utilizes proprietary wearable neuromodulation technology and is the only FDA authorized medical device to help reduce the symptoms of fibromyalgia.
  • "We are also looking forward to presenting new clinical data that builds on the use of Quell in fibromyalgia.

Magic Leap Announces Health Technology Early Access Program Participants for Magic Leap 2

Retrieved on: 
Wednesday, January 12, 2022
SYNCTHINK, Balance disorder, Radiation, Patient, Technology, Magic Leap, Population, Radiosurgery, Program, Brainlab, Health, Review, VP, Medi-Cal Access Program, CPT, Time, Microsoft 3D Viewer, LEAP, Efficiency, Education, Heru, Color, Mark (given name), Software, AR, Augmented reality, EAP, Physician, Video game, Medical device, Creative industries, Taxicab, Magic

PLANTATION, Fla., Jan. 12, 2022 /PRNewswire/ -- Magic Leap, Inc., today announced the participation of a number of key healthcare technology companies in the Early Access Program for Magic Leap 2, its second generation enterprise-focused augmented reality (AR) platform.

Key Points: 
  • PLANTATION, Fla., Jan. 12, 2022 /PRNewswire/ -- Magic Leap, Inc., today announced the participation of a number of key healthcare technology companies in the Early Access Program for Magic Leap 2, its second generation enterprise-focused augmented reality (AR) platform.
  • Early access to Magic Leap 2 devices will provide these healthcare technology companies the opportunity to finalize development of their Magic Leap 2 platform solutions, ahead of general commercial availability, which is scheduled for mid-2022.
  • As an Early Access Program participant for Magic Leap 2, SyncThink and Magic Leap will work together on clinical trials and explore the use of the Magic Leap 2 platform for Vestibular Disorders, with the shared goal of improving patient care and clinical outcomes in this patient population.
  • "The advancements in Magic Leap 2 significantly expand the uses of augmented reality in a healthcare setting," explained Jennifer Esposito, VP, Managing Director: Health at Magic Leap.

Vestibular First adds enhanced infection control to low-cost vertigo diagnostic tool

Retrieved on: 
Monday, January 10, 2022
Balance disorder, Audiology, Eye movement, Patient, Vertigo, Lists of diseases, Occupational therapy, Rehabilitation, Dizziness, COVID-19, Movement, Safety, PT, NCS, Computer, Otorhinolaryngology, Infection, DPT, Multimedia, FDA, Prevalence, Engineering, Software, COVID, Pharmaceutical industry, Medical imaging

BROOMALL, Pa., Jan. 10, 2022 /PRNewswire/ --Vestibular First LLC today announced it has added a new infection control measure to its FDA-cleared, low-cost tool for diagnosing dizziness, imbalance and vertigo, which affects over 10 million American adults.

Key Points: 
  • BROOMALL, Pa., Jan. 10, 2022 /PRNewswire/ --Vestibular First LLC today announced it has added a new infection control measure to its FDA-cleared, low-cost tool for diagnosing dizziness, imbalance and vertigo, which affects over 10 million American adults.
  • Eye movements are key information in putting together the puzzle of why a given patient may have dizziness and balance disorders like vertigo, said Vestibular First Co-Founder Patrick Esmonde.
  • Balance disorders like vertigo and dizziness can interfere with a patient's daily activities and can often be debilitating.
  • Insight Pro's durable silicone cushion can now be easily swapped with a new disposable cushion, which aids in infection control an important consideration during the COVID-19 pandemic.

Biodegradable Medical Plastics Market Size to grow by USD 261.00 million | Research Insights highlight the Growth in the Geriatric Population as Key Driver - Technavio

Retrieved on: 
Friday, November 19, 2021
Patient, Adoption, Starch, Ligament, Biomass, Time, Hospital, Balance disorder, Awareness, Rheumatoid arthritis, CVD, Prevalence, USD, Solution, Medicine, Oil, Arthritis, Tendon, FREE, Osteoarthritis, Bursitis, Growth, COVID, Medical device, Recycling

North America accounted for the largest biodegradable medical plastics market share in 2020 and will continue to retain its dominant position during the forecast period.

Key Points: 
  • North America accounted for the largest biodegradable medical plastics market share in 2020 and will continue to retain its dominant position during the forecast period.
  • This, in turn, is likely to fuel the demand for biodegradable medical plastics in North America.
  • This will further favor the growth of the biodegradable medical plastics market in the region during the forecast period.
  • Unlike conventional medical plastics, biodegradable medical plastics degrade completely and quickly without any hazardous emissions.

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

Retrieved on: 
Monday, September 27, 2021
Neck, Goal, Therapy, Review, Arthralgia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Muscular dystrophy, Degenerative disease, Death, Dystrophin, Safety, Mutation, SEC, Food, Upper respiratory tract infection, PMO, LinkedIn, Part, United States Patent and Trademark Office, Twitter, Male, Breathe Me, Hypotension, Sarepta, Magnesium, Incidence, SRPT, Bronchospasm, Patent, Vomiting, U.S. Securities and Exchange Commission, RNA transfection, Duchenne muscular dystrophy, RNA, Skin, Annual report, Sale, NASDAQ, Sarepta Therapeutics, FDA, Company, Rash, Hives, Flushing, Bruise, GLOBE, Investor Protection and Securities Reform Act of 2010, Gene editing, Instagram, Risk, Patient, Cough, Chemistry, DMD, Balance disorder, COVID-19, Pharmaceutical industry, Vaccine, Dentistry

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter. MOMENTUM is a global trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Key Points: 
  • MOMENTUM is a global trial investigating the use of SRP-5051, the Companys next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
  • The study will enroll between 20-40 patients between ages 7 to 21 amenable to exon 51 skipping who are nave to SRP-5051.
  • SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping.
  • EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Vestibular Disorders Association Announces Docuseries Life Rebalanced Chronicles: Shares Stories of Invisible Chronic Illness

Retrieved on: 
Wednesday, August 4, 2021
Neurological disorders, Balance disorder

Their message of hope is for everyone who struggles with invisible chronic illness or are navigating life's challenges.

Key Points: 
  • Their message of hope is for everyone who struggles with invisible chronic illness or are navigating life's challenges.
  • The six-episode docuseries airs weekly starting August 10, in conjunction with Balance Awareness Week (Sept. 19-25, 2021).
  • The series is a collaboration between the Vestibular Disorder Association (VeDA) and Kimberly Warner, filmmaker and founder of Unfixed Media .
  • The docuseries features nine vestibular patients who are learning to live with vestibular disorders.

2021 Pipeline Insights on Vestibular Schwannoma - Featuring AstraZeneca, Recursion Pharmaceuticals and Takeda Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 4, 2021
Health, Biotechnology, Nervous system, Neurological disorders, Organ systems, Audiology, Occupational safety and health, Branches of biology, Otorhinolaryngology, Vestibular schwannoma, Tinnitus, Balance disorder, Dizziness, Schwannoma

The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vestibular Schwannoma pipeline landscape.
  • Unilateral/asymmetric hearing loss and/or tinnitus and loss of balance/dizziness are early signs of a vestibular schwannoma.
  • Vestibular Schwannoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Three New Audiology Aides to Support Newport Beach Balance and Ear Institute

Retrieved on: 
Friday, May 24, 2019
Medical specialties, Health, Neurological disorders, Medicine, Otology, Audiology, Auditory system, Otorhinolaryngology, Balance disorder, Dizziness, Balance

NEWPORT BEACH, Calif., May 24, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has promoted three of its employees to the new position of Audiology Aides Alejandra Montoya, Naomi Vega and Raquel Redjai.

Key Points: 
  • NEWPORT BEACH, Calif., May 24, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has promoted three of its employees to the new position of Audiology Aides Alejandra Montoya, Naomi Vega and Raquel Redjai.
  • The audiology aides support the clinical team with patient care, allowing the audiologists more time to diagnose and treat balance and amplification patients.
  • "We are so fortunate to have such knowledgeable and experienced aides who provide such excellent care to our patients," said Dr. Jennifer Grace, Clinical Director, Newport-Mesa Audiology Balance & Ear Institute.
  • Newport-Mesa Audiology Balance & Ear Institute is one of the country's leading practices for the research, diagnosis and treatment of patients with vestibular dysfunction one of the leading causes of dizziness, vertigo and balance disorders.

Newport Beach Balance and Ear Institute Now Offers Virtual Reality Remote Treatment

Retrieved on: 
Tuesday, April 30, 2019
Organ systems, Neurological disorders, Nervous system, Medical specialties, Auditory system, Otology, RTT, Otorhinolaryngology, Balance disorder, Vertigo, Dizziness, Audiology

NEWPORT BEACH, Calif., April 30, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has developed a new technologically-advanced, patent pending virtual reality (VR) System for the Treatment of Vestibular Dysfunction, which provides home-based treatment for patients with dizziness, vertigo and imbalance.

Key Points: 
  • NEWPORT BEACH, Calif., April 30, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has developed a new technologically-advanced, patent pending virtual reality (VR) System for the Treatment of Vestibular Dysfunction, which provides home-based treatment for patients with dizziness, vertigo and imbalance.
  • Part of the Institute's proprietary method of treatment called Advanced Vestibular Treatment (AVT), the Institute has been researching and developing this new home-based VR treatment system for several years.
  • Newport-Mesa Audiology Balance & Ear Institute is one of the country's leading practices for the research, diagnosis and treatment of patients with vestibular dysfunction one of the leading causes of dizziness, vertigo and balance disorders.
  • 500 Old Newport Blvd., Suite 101, Newport Beach, CA 92663 | 949.642.7935 | http://www.dizziland.com .

SCALE-1 PORTAL Unveils MoveR, an Innovative Application for Balance Disorders Treatment in Mixed Reality, at the CES 2019

Retrieved on: 
Wednesday, December 19, 2018
Health, Medicine, Neurological disorders, Balance disorder, Dizziness, Consumer Electronics Show, Physical therapy, Balance

SCALE-1 PORTAL launches MoveR, an immersive therapy in mixed reality for dizziness and balance disorders, at the CES 2019 in Las Vegas, on January 8, 2019.

Key Points: 
  • SCALE-1 PORTAL launches MoveR, an immersive therapy in mixed reality for dizziness and balance disorders, at the CES 2019 in Las Vegas, on January 8, 2019.
  • The project has received support from Thierry Guillot, aphysiotherapist specialized in balance disorders.
  • More than 30 people were able to test the product, including Clotilde Ballbe - a specialist in balancing system disorders.
  • Founded in 2014, the company provides immersive solutions and contents for major actors in the Manufacturing, Real-Estate & Construction, and Location-Based Entertainment sectors.